TEAM.NASDAQAtlassian CORP

Form 4: Atlassian Co-CEO Michael Cannon-Brookes Reports Stock Sales Under 10b5-1 Trading Plan

Sentiment:

SEC Form 4 Filing


Michael Cannon-Brookes, Co-CEO of Atlassian, reports multiple sales of Class A Common Stock on April 2, 2024, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

  • Michael Cannon-Brookes, Co-CEO and Co-Founder of Atlassian, filed a Form 4 disclosing sales of Class A Common Stock on April 2, 2024.
  • The sales were executed under a Rule 10b5-1 trading plan adopted on February 21, 2023.
  • The transactions involved multiple sales at varying prices, ranging from $191.14 to $196.30 per share.
  • A total of 8,241 shares were sold, resulting in a decrease in the number of shares indirectly beneficially owned through a trust.
  • Following the reported transactions, Cannon-Brookes indirectly beneficially owns 502,718 shares through the Cannon-Brookes Head Trust.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock sales by an executive. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.

Industry Context

This filing is a routine disclosure of stock sales by a company insider and is a common practice for executives to diversify their holdings or manage personal finances. The use of a 10b5-1 trading plan suggests that these sales were pre-planned and not based on any inside information.

Key Dates

DateDescription
February 21, 2023Date the Reporting Person adopted the Rule 10b5-1 trading plan
April 02, 2024Date of the reported stock sales
April 03, 2024Date of the signature on the Form 4 filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.